Brian Powl
Corporate Officer/Principal bij KURA ONCOLOGY, INC.
Vermogen: 621 962 $ op 31-03-2024
Profiel
Brian T.
Powl is currently the Chief Commercial Officer at Kura Oncology, Inc. He previously worked as the Vice President-Global Commercial CAR T Lead at Celgene Corp., Senior VP-Commercial Development & Marketing at MEI Pharma, Inc., and Chief Commercial Officer at Fate Therapeutics, Inc. Powl received his undergraduate degree from the University of California San Diego and his MBA from The Wharton School of the University of Pennsylvania.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
KURA ONCOLOGY, INC.
0.02% | 02-01-2024 | 15 000 ( 0.02% ) | 319 950 $ | 31-03-2024 |
FATE THERAPEUTICS, INC.
0.04% | 05-07-2023 | 41 146 ( 0.04% ) | 302 012 $ | 31-03-2024 |
Actieve functies van Brian Powl
| Bedrijven | Functie | Begin |
|---|---|---|
| KURA ONCOLOGY, INC. | Corporate Officer/Principal | 14-08-2023 |
Eerdere bekende functies van Brian Powl
| Bedrijven | Functie | Einde |
|---|---|---|
| CELGENE | Corporate Officer/Principal | - |
| FATE THERAPEUTICS, INC. | Corporate Officer/Principal | - |
| MEI PHARMA, INC. | Sales & Marketing | - |
Opleiding van Brian Powl
| University of California San Diego | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| KURA ONCOLOGY, INC. | Health Technology |
| MEI PHARMA, INC. | Health Technology |
| FATE THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
